CN115448916B - Tyk2抑制剂及其用途 - Google Patents
Tyk2抑制剂及其用途Info
- Publication number
- CN115448916B CN115448916B CN202211114285.2A CN202211114285A CN115448916B CN 115448916 B CN115448916 B CN 115448916B CN 202211114285 A CN202211114285 A CN 202211114285A CN 115448916 B CN115448916 B CN 115448916B
- Authority
- CN
- China
- Prior art keywords
- compound
- xxi
- compounds
- nitrogen
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (20)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662408464P | 2016-10-14 | 2016-10-14 | |
| US62/408,464 | 2016-10-14 | ||
| US201662410327P | 2016-10-19 | 2016-10-19 | |
| US201662410334P | 2016-10-19 | 2016-10-19 | |
| US62/410,327 | 2016-10-19 | ||
| US62/410,334 | 2016-10-19 | ||
| US201662413829P | 2016-10-27 | 2016-10-27 | |
| US62/413,829 | 2016-10-27 | ||
| US201662415920P | 2016-11-01 | 2016-11-01 | |
| US62/415,920 | 2016-11-01 | ||
| US201762468807P | 2017-03-08 | 2017-03-08 | |
| US201762468767P | 2017-03-08 | 2017-03-08 | |
| US201762468749P | 2017-03-08 | 2017-03-08 | |
| US62/468,807 | 2017-03-08 | ||
| US62/468,749 | 2017-03-08 | ||
| US62/468,767 | 2017-03-08 | ||
| US201762546278P | 2017-08-16 | 2017-08-16 | |
| US62/546,278 | 2017-08-16 | ||
| CN201780069795.3A CN109952303B (zh) | 2016-10-14 | 2017-10-13 | Tyk2抑制剂及其用途 |
| PCT/US2017/056555 WO2018071794A1 (en) | 2016-10-14 | 2017-10-13 | Tyk2 inhibitors and uses thereof |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201780069795.3A Division CN109952303B (zh) | 2016-10-14 | 2017-10-13 | Tyk2抑制剂及其用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115448916A CN115448916A (zh) | 2022-12-09 |
| CN115448916B true CN115448916B (zh) | 2026-04-28 |
Family
ID=61906011
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211114285.2A Active CN115448916B (zh) | 2016-10-14 | 2017-10-13 | Tyk2抑制剂及其用途 |
| CN201780069795.3A Active CN109952303B (zh) | 2016-10-14 | 2017-10-13 | Tyk2抑制剂及其用途 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201780069795.3A Active CN109952303B (zh) | 2016-10-14 | 2017-10-13 | Tyk2抑制剂及其用途 |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US10323036B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3848370B1 (cg-RX-API-DMAC7.html) |
| JP (4) | JP7082130B2 (cg-RX-API-DMAC7.html) |
| CN (2) | CN115448916B (cg-RX-API-DMAC7.html) |
| AU (3) | AU2017342464B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3039202A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2930198T3 (cg-RX-API-DMAC7.html) |
| IL (2) | IL315777A (cg-RX-API-DMAC7.html) |
| TW (2) | TWI763722B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018071794A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016138352A1 (en) | 2015-02-27 | 2016-09-01 | Nimbus Lakshmi, Inc. | Tyk2 inhibitors and uses thereof |
| EP4327809A3 (en) | 2015-09-02 | 2024-04-17 | Takeda Pharmaceutical Company Limited | Tyk2 inhibitors and uses thereof |
| TWI763722B (zh) | 2016-10-14 | 2022-05-11 | 美商林伯士拉克許米公司 | Tyk2抑制劑及其用途 |
| GB201617871D0 (en) * | 2016-10-21 | 2016-12-07 | Sareum Limited | Pharmaceutical compounds |
| CN110300590A (zh) | 2016-10-21 | 2019-10-01 | 林伯士拉克许米公司 | Tyk2抑制剂及其用途 |
| AU2018230737B2 (en) | 2017-03-08 | 2022-09-22 | Takeda Pharmaceutical Company Limited | Tyk2 inhibitors, uses, and methods for production thereof |
| IL317854A (en) | 2017-07-28 | 2025-02-01 | Takeda Pharmaceuticals Co | TYK2 inhibitors and their uses |
| TW201940483A (zh) | 2018-03-12 | 2019-10-16 | 美商艾伯維有限公司 | 酪胺酸激酶2介導的傳訊之抑制劑 |
| JP7478142B2 (ja) * | 2018-06-07 | 2024-05-02 | ディスアーム セラピューティクス, インコーポレイテッド | Sarm1阻害剤 |
| EP3801503A4 (en) | 2018-06-07 | 2021-12-08 | Disarm Therapeutics, Inc. | INHIBITORS OF SARM1 |
| EP3846793B1 (en) | 2018-09-07 | 2024-01-24 | PIC Therapeutics, Inc. | Eif4e inhibitors and uses thereof |
| JP7619951B2 (ja) | 2018-10-15 | 2025-01-22 | 武田薬品工業株式会社 | Tyk2阻害剤およびその使用 |
| WO2020112937A1 (en) * | 2018-11-30 | 2020-06-04 | Nimbus Lakshmi, Inc. | Tyk2 inhibitors and uses thereof |
| CA3126034A1 (en) * | 2019-01-23 | 2020-07-30 | Nimbus Lakshmi, Inc. | Tyk2 inhibitors and uses thereof |
| WO2020159904A1 (en) * | 2019-01-30 | 2020-08-06 | Bristol-Myers Squibb Company | Amide-disubstituted pyridine or pyridazine compounds |
| WO2020222773A1 (en) | 2019-04-30 | 2020-11-05 | Celgene Corporation | Combination therapies comprising apremilast and tyk2 inhibitors |
| GB2606804B (en) | 2019-07-17 | 2023-12-27 | 2692372 Ontario Inc | Benzenesulfonamide derivatives and uses thereof |
| KR20220059519A (ko) * | 2019-09-11 | 2022-05-10 | 화이자 인코포레이티드 | 키나제 억제제에 의한 한선염의 치료 |
| US12606556B2 (en) | 2020-02-26 | 2026-04-21 | Beone Medicines I Gmbh | TYK-2 inhibitor |
| AR121506A1 (es) | 2020-03-03 | 2022-06-08 | Pic Therapeutics Inc | Inhibidores del eif4e y sus usos |
| WO2021237121A1 (en) * | 2020-05-21 | 2021-11-25 | Gossamer Bio Services, Inc. | Substituted pyridines |
| US20240043435A1 (en) | 2020-06-22 | 2024-02-08 | Beigene, Ltd. | Tyk-2 inhibitor |
| WO2022083560A1 (zh) * | 2020-10-19 | 2022-04-28 | 南京药石科技股份有限公司 | Tyk2选择性抑制剂及其用途 |
| US20240018153A1 (en) | 2020-11-20 | 2024-01-18 | 2692372 Ontario, Inc. | Benzenesulfonamide derivatives and uses thereof |
| US12668594B2 (en) | 2020-12-23 | 2026-06-30 | Sudo Biosciences Limited | TYK2 inhibitors and uses thereof |
| TW202302583A (zh) | 2021-02-19 | 2023-01-16 | 英商蘇多生物科學有限公司 | Tyk2抑制劑及其用途 |
| IL305119A (en) | 2021-02-19 | 2023-10-01 | Sudo Biosciences Ltd | Tyk2 inhibitors and uses thereof |
| KR20230159421A (ko) | 2021-02-19 | 2023-11-21 | 수도 바이오사이언시즈 리미티드 | Tyk2 억제제 및 이의 용도 |
| EP4308556A4 (en) | 2021-03-16 | 2025-02-19 | Anrui Biomedical Technology (Guangzhou) Co., Ltd. | Amino heteroaryl compounds and compositions |
| JP7740849B2 (ja) * | 2021-05-04 | 2025-09-17 | シャンハイ ゼイ バイオテクノロジー カンパニー リミテッド | 含窒素複素環ピリジン化合物 |
| CN115466289B (zh) * | 2021-06-11 | 2026-07-03 | 爱科诺生物医药(苏州)有限公司 | 具有tyk2抑制活性的化合物,包含其的药物组合物,及其应用 |
| US12157732B2 (en) | 2021-08-25 | 2024-12-03 | PIC Therapeutics, Inc. | eIF4E inhibitors and uses thereof |
| IL310924A (en) | 2021-08-25 | 2024-04-01 | Pic Therapeutics Inc | Eif4e inhibitors and uses thereof |
| US20240390369A1 (en) | 2021-09-30 | 2024-11-28 | Bristol-Myers Squibb Company | Methods for determining responsiveness to tyk2 inhibitors |
| KR20240111312A (ko) | 2021-10-25 | 2024-07-16 | 카이메라 쎄라퓨틱스 인코포레이티드 | Tyk2 분해제 및 이의 용도 |
| MX2024007713A (es) * | 2021-12-23 | 2024-07-01 | Beigene Switzerland Gmbh | Formas solidas de un inhibidor de tyk2, metodo de preparacion y uso de estas. |
| WO2023220046A1 (en) * | 2022-05-10 | 2023-11-16 | Biogen Ma Inc. | Tyk2 inhibitors |
| WO2023248010A2 (en) | 2022-06-23 | 2023-12-28 | Synovo Gmbh | Targeted modulators of jak3 for treatment of inflammatory and autoimmune diseases |
| US20240124450A1 (en) | 2022-09-21 | 2024-04-18 | Pfizer Inc. | Novel SIK Inhibitors |
| CN115819429A (zh) * | 2022-12-13 | 2023-03-21 | 成都睿智化学研究有限公司 | 一种5-氯-2,3-二氢呋喃[2,3-c]吡啶的合成方法 |
| WO2024193689A1 (zh) * | 2023-03-23 | 2024-09-26 | 广东东阳光药业股份有限公司 | 吡啶并吡咯衍生物及其在药物中的用途 |
| WO2024211708A1 (en) * | 2023-04-06 | 2024-10-10 | Myrobalan Therapeutics, Inc. | Tyk2 inhibitors for treatment of glaucoma |
| WO2024217523A1 (en) * | 2023-04-20 | 2024-10-24 | Myrobalan Therapeutics Nanjing Co. Ltd | Selective tky2 inhibitors and uses thereof |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003057689A1 (en) * | 2002-01-02 | 2003-07-17 | Fujisawa Pharmaceutical Co., Ltd. | Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them |
| CN101421262A (zh) * | 2006-02-06 | 2009-04-29 | Irm责任有限公司 | 作为蛋白激酶抑制剂的化合物和组合物 |
| CN101437512A (zh) * | 2006-01-27 | 2009-05-20 | 阿雷生物药品公司 | 葡萄糖激酶活化剂 |
| CN101686675A (zh) * | 2007-03-20 | 2010-03-31 | 史密丝克莱恩比彻姆公司 | 化合物 |
| JP2010516788A (ja) * | 2007-01-31 | 2010-05-20 | サイトピア・リサーチ・ピーティーワイ・リミテッド | チオピリミジンベースの化合物およびその使用 |
| CN102548984A (zh) * | 2009-04-28 | 2012-07-04 | 安姆根有限公司 | Pi3激酶和/或mtor的抑制剂 |
| CN104254533A (zh) * | 2012-01-13 | 2014-12-31 | 百时美施贵宝公司 | 用作激酶抑制剂的噻唑或噻二唑取代的吡啶基化合物 |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR901228A (fr) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Système d'aimant à entrefer annulaire |
| GB599891A (en) * | 1944-11-17 | 1948-03-23 | Gen Aniline & Film Corp | 1-substituted-2,5-diketo-7-methyl-pyrimido-pyrazoles and process of preparing the same |
| US4709016A (en) | 1982-02-01 | 1987-11-24 | Northeastern University | Molecular analytical release tags and their use in chemical analysis |
| US5650270A (en) | 1982-02-01 | 1997-07-22 | Northeastern University | Molecular analytical release tags and their use in chemical analysis |
| US5516931A (en) | 1982-02-01 | 1996-05-14 | Northeastern University | Release tag compounds producing ketone signal groups |
| US4650750A (en) | 1982-02-01 | 1987-03-17 | Giese Roger W | Method of chemical analysis employing molecular release tag compounds |
| OA12118A (en) | 1999-12-10 | 2006-05-04 | Pfizer Prod Inc | PyrroloÄ2,3-dÜpyrimidine compounds. |
| PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| KR100833371B1 (ko) | 2001-04-27 | 2008-05-28 | 젠야쿠코교가부시키가이샤 | 헤테로시클릭 화합물 및 이를 유효 성분으로 하는 항종양제 |
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| MXPA05001766A (es) | 2002-08-14 | 2005-08-19 | Atugen Ag | Uso de proteina quinasa n beta. |
| WO2004089925A1 (en) | 2003-04-03 | 2004-10-21 | Semafore Pharmaceuticals, Inc. | Pi-3 kinase inhibitor prodrugs |
| ES2382377T3 (es) | 2003-05-30 | 2012-06-07 | Gemin X Pharmaceuticals Canada Inc. | Compuestos triheterocíclicos, composiciones, y métodos para tratar cáncer |
| WO2005007623A2 (en) | 2003-07-03 | 2005-01-27 | The Trustees Of The University Of Pennsylvania | Inhibition of syk kinase expression |
| AU2005219776B2 (en) | 2004-03-04 | 2010-07-08 | Kissei Pharmaceutical Co., Ltd. | Nitrogenous fused-ring derivatives, medicinal compositions containing the derivatives, and use thereof as drugs |
| LT2612862T (lt) | 2004-05-13 | 2017-01-25 | Icos Corporation | Chinazolinonai kaip žmogaus fosfatidilinozitol-3-kinazės delta inhibitoriai |
| US7449458B2 (en) | 2005-01-19 | 2008-11-11 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
| ES2493466T3 (es) | 2005-05-12 | 2014-09-11 | Abbvie Bahamas Ltd. | Promotores de la apoptosis |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| US7402325B2 (en) | 2005-07-28 | 2008-07-22 | Phoenix Biotechnology, Inc. | Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander |
| HRP20140975T1 (hr) | 2005-10-07 | 2014-11-21 | Exelixis, Inc. | Derivati n-(3-amino-hinoksalin-2-il)-sulfonamida i njihova uporaba kao inhibitora fosfatidilinozitol 3-kinaze |
| WO2007053452A1 (en) | 2005-11-01 | 2007-05-10 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
| HUE028588T2 (hu) | 2005-12-13 | 2016-12-28 | Incyte Holdings Corp | Heteroaril-szubsztituált pirrolo[2,3-b]piridinek és pirrolo[2,3-b]pirimidinek mint Janus-kináz inhibitorok |
| JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| KR101533461B1 (ko) | 2006-04-26 | 2015-07-02 | 에프. 호프만-라 로슈 아게 | Pi3k저해제로 유용한 티에노[3,2-d]피리미딘 유도체 |
| EP2529621B1 (en) | 2006-09-22 | 2016-10-05 | Pharmacyclics LLC | Inhibitors of bruton's tyrosine kinase |
| HUE029188T2 (en) | 2007-03-12 | 2017-03-28 | Ym Biosciences Australia Pty | Phenylamino-pyrimidine compounds and their use |
| US8394794B2 (en) | 2007-03-23 | 2013-03-12 | Regents Of The University Of Minnesota | Therapeutic compounds |
| PE20090717A1 (es) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
| GB0719644D0 (en) * | 2007-10-05 | 2007-11-14 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| AU2008345225A1 (en) * | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| MY165582A (en) | 2008-03-11 | 2018-04-05 | Incyte Holdings Corp | Azetidine and cyclobutane derivatives as jak inhibitors |
| EP2299816B1 (en) * | 2008-06-18 | 2013-11-13 | Merck Sharp & Dohme Corp. | Inhibitors of janus kinases |
| US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| EP2588471A1 (en) * | 2010-06-30 | 2013-05-08 | Amgen Inc. | Heterocyclic compounds and their use as inhibitors of pi3k activity |
| AU2011328237A1 (en) | 2010-11-09 | 2013-05-23 | Cellzome Limited | Pyridine compounds and aza analogues thereof as TYK2 inhibitors |
| US9033542B2 (en) * | 2010-11-16 | 2015-05-19 | Dialight Corporation | LED luminaire utilizing an extended and non-metallic enclosure |
| KR20140009259A (ko) * | 2010-11-19 | 2014-01-22 | 에프. 호프만-라 로슈 아게 | 피라졸로피리딘 및 tyk2 억제제로서 이의 용도 |
| ES2686500T3 (es) * | 2012-01-13 | 2018-10-18 | Bristol-Myers Squibb Company | Compuestos de piridilo sustituidos con heterocíclicos, útiles como inhibidores de cinasas |
| WO2013106614A1 (en) * | 2012-01-13 | 2013-07-18 | Bristol-Myers Squibb Company | Triazolyl-substituted pyridyl compounds useful as kinase inhibitors |
| EP2922841B8 (en) | 2012-11-08 | 2017-08-02 | Bristol-Myers Squibb Company | Alkyl-amide-substituted pyridyl compounds useful as modulators of il-12, il-23 and/or ifn alpha responses |
| HRP20220766T1 (hr) | 2012-11-08 | 2022-09-16 | Bristol-Myers Squibb Company | Amidom-supstituirani heterociklički spojevi korisni kao modulatori il-12, il-23 i/ili ifn alfa odgovora |
| AU2014211856C1 (en) * | 2013-02-02 | 2018-04-12 | Centaurus Biopharma Co., Ltd. | Substituted 2-aminopyridine protein kinase inhibitor |
| WO2014210354A1 (en) * | 2013-06-28 | 2014-12-31 | Genentech, Inc. | Azaindazole compounds as inhibitors of t790m containing egfr mutants |
| US20160222014A1 (en) * | 2013-09-10 | 2016-08-04 | Asana Biosciences, Llc | Compounds for regulating fak and/or src pathways |
| AR094537A1 (es) * | 2013-11-07 | 2015-08-12 | Bristol Myers Squibb Co | COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O IFNa |
| WO2015073267A1 (en) * | 2013-11-15 | 2015-05-21 | Calitor Sciences, Llc | Substituted heteroaryl compounds and methods of use |
| ES2702126T3 (es) | 2013-12-10 | 2019-02-27 | Bristol Myers Squibb Co | Compuestos de imidazopiridazina útiles como moduladores de respuestas a IL-12, IL-23 y/o IFN alfa |
| US9340540B2 (en) | 2014-02-28 | 2016-05-17 | Nimbus Lakshmi, Inc. | TYK2 inhibitors and uses thereof |
| NO2721710T3 (cg-RX-API-DMAC7.html) * | 2014-08-21 | 2018-03-31 | ||
| WO2016138352A1 (en) * | 2015-02-27 | 2016-09-01 | Nimbus Lakshmi, Inc. | Tyk2 inhibitors and uses thereof |
| CN107849039B (zh) * | 2015-06-24 | 2020-07-03 | 百时美施贵宝公司 | 经杂芳基取代的氨基吡啶化合物 |
| TWI763722B (zh) | 2016-10-14 | 2022-05-11 | 美商林伯士拉克許米公司 | Tyk2抑制劑及其用途 |
-
2017
- 2017-10-13 TW TW106135165A patent/TWI763722B/zh active
- 2017-10-13 WO PCT/US2017/056555 patent/WO2018071794A1/en not_active Ceased
- 2017-10-13 ES ES17860009T patent/ES2930198T3/es active Active
- 2017-10-13 IL IL315777A patent/IL315777A/en unknown
- 2017-10-13 CN CN202211114285.2A patent/CN115448916B/zh active Active
- 2017-10-13 JP JP2019541679A patent/JP7082130B2/ja active Active
- 2017-10-13 US US15/783,250 patent/US10323036B2/en active Active
- 2017-10-13 IL IL265922A patent/IL265922B2/en unknown
- 2017-10-13 CA CA3039202A patent/CA3039202A1/en active Pending
- 2017-10-13 EP EP21157963.6A patent/EP3848370B1/en active Active
- 2017-10-13 EP EP17860009.4A patent/EP3526222B1/en active Active
- 2017-10-13 AU AU2017342464A patent/AU2017342464B2/en active Active
- 2017-10-13 CN CN201780069795.3A patent/CN109952303B/zh active Active
- 2017-10-13 TW TW111113673A patent/TWI825663B/zh active
-
2019
- 2019-04-30 US US16/399,296 patent/US10793574B2/en active Active
-
2020
- 2020-05-04 US US16/865,924 patent/US11220508B2/en active Active
-
2021
- 2021-09-03 AU AU2021225251A patent/AU2021225251A1/en not_active Abandoned
- 2021-09-17 US US17/448,013 patent/US20220073527A1/en not_active Abandoned
-
2022
- 2022-01-04 JP JP2022000195A patent/JP7498200B2/ja active Active
-
2023
- 2023-06-01 JP JP2023091142A patent/JP2023106606A/ja not_active Withdrawn
- 2023-09-26 AU AU2023237060A patent/AU2023237060B2/en active Active
-
2025
- 2025-11-25 JP JP2025202716A patent/JP2026035684A/ja active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003057689A1 (en) * | 2002-01-02 | 2003-07-17 | Fujisawa Pharmaceutical Co., Ltd. | Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them |
| CN101437512A (zh) * | 2006-01-27 | 2009-05-20 | 阿雷生物药品公司 | 葡萄糖激酶活化剂 |
| CN101421262A (zh) * | 2006-02-06 | 2009-04-29 | Irm责任有限公司 | 作为蛋白激酶抑制剂的化合物和组合物 |
| JP2010516788A (ja) * | 2007-01-31 | 2010-05-20 | サイトピア・リサーチ・ピーティーワイ・リミテッド | チオピリミジンベースの化合物およびその使用 |
| CN101686675A (zh) * | 2007-03-20 | 2010-03-31 | 史密丝克莱恩比彻姆公司 | 化合物 |
| CN102548984A (zh) * | 2009-04-28 | 2012-07-04 | 安姆根有限公司 | Pi3激酶和/或mtor的抑制剂 |
| CN104254533A (zh) * | 2012-01-13 | 2014-12-31 | 百时美施贵宝公司 | 用作激酶抑制剂的噻唑或噻二唑取代的吡啶基化合物 |
Non-Patent Citations (3)
| Title |
|---|
| Structure-Based Design of a Novel Series of Potent, Selective Inhibitors of the Class I Phosphatidylinositol 3-Kinases;Adrian L. Smith等;《Journal of Medicinal Chemistry》;20120501;第55卷;第5188-5129页 * |
| Synthesis and Biological Evaluation of Pyrimidine-Based Dual Inhibitors of Human Epidermal Growth Factor Receptor 1 (HER-1) and HER-2 Tyrosine Kinases;Mi Young Cha等;《Journal of Medicinal Chemistry》;20120228;第55卷;第2846-2857页 * |
| Xiaohu Ouyang等.Synthesis and structure–activity relationships of 1,2,4-triazoles as a novel class of potent tubulin polymerization inhibitors.《Bioorganic & Medicinal Chemistry Letters》.2005,第15卷第5154-5159页. * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7498200B2 (ja) | Tyk2阻害剤およびその使用 | |
| JP7530360B2 (ja) | Tyk2阻害剤およびその使用 | |
| JP7699052B2 (ja) | Tyk2阻害剤およびその使用 | |
| AU2019360941A1 (en) | TYK2 inhibitors and uses thereof | |
| HK40055822A (en) | Tyk2 inhibitors and uses thereof | |
| HK40055822B (en) | Tyk2 inhibitors and uses thereof | |
| HK40009936A (en) | Tyk2 inhibitors and uses thereof | |
| HK40009936B (en) | Tyk2 inhibitors and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20231129 Address after: Osaka, Japan Applicant after: TAKEDA PHARMACEUTICAL Co.,Ltd. Address before: Massachusetts Applicant before: NIMBUS LAKSHMI, Inc. |
|
| TA01 | Transfer of patent application right | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |